Abstracts Archive - Page 2169 of 2607 - ACR Meeting Abstracts

Abstract Number: 968 • 2014 ACR/ARHP Annual Meeting
Priming of WNT Signalling during Fibrosis Is Mediated By TGF-β Induced Axin-2 Downregulation
Justin Gillespie¹, Emma C. Derrett-Smith², Michael McDermott¹, Paul Emery³, Christopher P Denton⁴ and Francesco Del Galdo³, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Centre for Rheumatology and Connective Tissue Diseases,, UCL Medical School Royal Free Campus, London, United Kingdom, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁴Centre for Rheumatology and Connective Tissue Disease, UCL Medical School Royal Free Campus, London, United Kingdom

Background/Purpose Systemic Sclerosis (SSc) is characterized by autoimmune activation, vasculopathy and tissue fibrosis. Recently, activation of the Wnt/β-catenin signaling pathway in SSc fibroblasts has been…
Abstract Number: 966 • 2014 ACR/ARHP Annual Meeting
Adiponectin Is an Endogenous Anti-Fibrotic and Target in Systemic Sclerosis: Novel Link Between Fibrosis and Metabolism
Feng Fang¹, Roberta G. Marangoni¹, Xingchun Zhou², Wen Hong³, Boping Ye³, Asano Yoshihide⁴, Shinichi Sato⁵, Yuri Masui⁶, Chengning Zhang⁷, Katja Lakota⁸, Jun Wei⁹, Monique E. Hinchcliff⁷, Philipp Scherer¹⁰, Laszlo Otvos¹¹ and John Varga¹², ¹Division of Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, ²College of Life and Science, China Pharmaceutical University, Nanjing, China, ³China Pharmaceutical University, Nanjing, China, ⁴University of Tokyo, Tokyo, Japan, ⁵Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo, Japan, ⁶Department of Dermatology, University of Tokyo, Tokyo, Japan, ⁷Northwestern University, Feinberg School of Medicine, Chicago, IL, ⁸Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL, ⁹Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, ¹⁰University of Texas Southwestern Medical Center, Dallas, TX, ¹¹Temple University, Philadelphia, PA, ¹²Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose :Systemic sclerosis (SSc) skin fibrosis is associated with attenuated cutaneous adipose tissue and adipogenic gene expression. Levels of the adipose-derived cytokine adiponectin (APN) and…
Abstract Number: 965 • 2014 ACR/ARHP Annual Meeting
Blockade of TLR4 Signaling By TAK242 Ameliorates Experimental Organ Fibrosis
Swati Bhattacharyya¹, Wenxia Wang¹, Zenshiro Tamaki², Yasuhiro Tsukimi³, Masashi Yamasaki³ and John Varga⁴, ¹Medicine/Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, ²Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL, ³Takeda Pharmaceutical Company Limited, Kanagawa, Japan, ⁴Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose Our recent studies implicate innate immune signaling through Toll like receptor 4 (TLR4) in scleroderma pathogenesis. Aberrant production and accumulation of the endogenous TLR4…
Abstract Number: 964 • 2014 ACR/ARHP Annual Meeting
Skin Collagen Synthesis Rates Distinguish Between Early and Late Diffuse Scleroderma Patients
Claire Emson¹, Martin Decaris¹, Michelle Gatmaitan¹, Flora Luo¹, Dan Holochwost¹, Simplicia FloraCruz¹, Thomas Angel¹, Kelvin Li¹, Marc Hellerstein¹, Fredrick M. Wigley², Scott Turner^1,3 and Francesco Boin², ¹KineMed Inc., Emeryville, CA, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³5980 Horton Street, Suite 470, KineMed Inc., Emeryville, CA
Background/Purpose The synthesis and degradation of extracellular matrix (ECM), particularly collagen, is one of the central mechanisms perturbed in scleroderma (SSc). Understanding the kinetics of…
Abstract Number: 962 • 2014 ACR/ARHP Annual Meeting
A Systematic Review and Network Meta-Analysis of the Risk of Serious Infections with Immunosuppressives for Lupus Nephritis
Jasvinder A. Singh¹, Alomgir Hossain², Ahmed Kotb² and George Wells³, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Ottawa, Ottawa, ON, Canada, ³Cardiovascular Resarch Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada
Background/Purpose To compare the risk of serious infections of immunosuppressive medications used for the treatment of lupus nephritis. Methods We performed an up to date…
Abstract Number: 979 • 2014 ACR/ARHP Annual Meeting
Genome-Wide Association Study for Severe Radiographic Knee Osteoarthritis
Youfang Liu¹, Michelle Yau², Laura Yerges-Armstrong³, Braxton Mitchell³, Rebecca D. Jackson⁴, Marc C. Hochberg⁵, Shad Smith⁶, William Maixner⁶, Luda Diatchenko⁷ and Joanne M. Jordan⁸, ¹Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, ²Epidemiology and Public Health, University of Maryland, Baltimore,, MD, ³Medicine, University of Maryland School of Medicine, Baltimore, MD, ⁴Division of Endocrinology, Diabetes, & Metabolism, Department of Internal Medicine, The Ohio State University, Columbus, OH, ⁵Division of Rheumatology & Clinical Immunology, University of Maryland School of Medicine, Baltimore, MD, ⁶Regional Center for Neurosensory Disorders, School of Dentistry,, University of North Carolina, Chapel Hill, NC, ⁷McGill University, Montreal, QC, Canada, ⁸University of North Carolina Dept of Epidemiology, Chapel Hill, NC
Background/Purpose Knee osteoarthritis (OA) is a heritable common joint disorder. In previously reported genetic studies, cases were usually defined with a radiographic Kellgren and Lawrence…
Abstract Number: 978 • 2014 ACR/ARHP Annual Meeting
Socioeconomic Status Measures Are Associated with Increasing Pain, Stiffness and Physical Function Among Individuals with Knee and Hip Osteoarthritis
Rebecca J. Cleveland¹, Jordan B. Renner², Joanne M. Jordan³ and Leigh F. Callahan⁴, ¹Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of North Carolina Department of Radiology, Chapel Hill, NC, ³University of North Carolina Dept of Epidemiology, Chapel Hill, NC, ⁴Thurston Arthritis Res Ctr, University of North Carolina, Chapel Hill, NC
Background/Purpose The determinants of disability progression (DP) among those with knee and/or hip osteoarthritis (OA) are not well known. Our aim was to explore whether…
Abstract Number: 963 • 2014 ACR/ARHP Annual Meeting
Reduction in Proteinuria and Normalization of C4 Complement Levels Predict Response to Treatment of Lupus Nephritis with Low-Dose Pulse Cyclophosphamide and Abatacept
Sarah Goglin¹, David Wofsy², Miriam G. Cisternas³ and Maria Dall'era¹, ¹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³MGC Data Services, Carlsbad, CA
Background/Purpose: The response to treatment of lupus nephritis is unpredictable. There is a need to identify clinical and biochemical characteristics that can predict treatment outcome…
Abstract Number: 967 • 2014 ACR/ARHP Annual Meeting
Mir-145 Protects Against Skin Fibrosis in Vivo by targeting TGF-β Signaling
Serena Vettori^1,2, Christian Beyer³, Matthias Brock¹, Naoki Iwamoto¹, Britta Maurer¹, Michelle Trenkmann¹, Astrid Jüngel¹, Renate E. Gay¹, Maurizio Calcagni⁴, Gabriele Valentini⁵, Steffen Gay¹, Joerg H. W. Distler³ and Oliver Distler¹, ¹Center of Experimental Rheumatology, Zurich University Hospital, Zurich, Switzerland, ²Internal and Experimental Medicine, Second University of Naples, Naples, Italy, ³Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Division of Plastic Surgery and Hand Surgery, University Hospital Zurich, Zurich, Switzerland, ⁵Internal and Experimental Medicine, Second University of Naples, Napoli, Italy
Background/Purpose In vitro, miR-145 exerts anti-fibrotic effects in systemic sclerosis (SSc) by downregulating TGF-β signaling. In turn, ectopic TGF-β downregulates miR-145 thereby optimizing TGF-β signaling…
Abstract Number: 953 • 2014 ACR/ARHP Annual Meeting
Secukinumab, a Human Anti–Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study
Philip J. Mease¹, Iain B. McInnes², Bruce Kirkham³, Arthur Kavanaugh⁴, Proton Rahman⁵, Désirée van der Heijde⁶, Robert Landewé⁷, Peter Nash⁸, Luminita Pricop⁹, Jiacheng Yuan¹⁰, Hanno Richards¹¹ and Shephard Mpofu¹², ¹Swedish Medical Center and University of Washington, Seattle, WA, ²University of Glasgow, Glasgow, United Kingdom, ³Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, ⁴UCSD School of Medicine, La Jolla, CA, ⁵Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁷Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁸University of Queensland, Brisbane, Australia, ⁹Integrated Hospital Care (IHC) Franchise, Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland, ¹²Novartis Pharma AG, Basel, Switzerland
Background/Purpose Secukinumab has demonstrated significant and rapid efficacy in the treatment of psoriasis in two phase 3 studies. We present the first randomized, multicenter, double-blind,…
Abstract Number: 952 • 2014 ACR/ARHP Annual Meeting
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Evaluate the Efficacy and Safety of Clazakizumab, an Anti-IL-6 Monoclonal Antibody, in Adults with Active Psoriatic Arthritis
Philip J. Mease¹, A B Gottlieb², A Berman³, E Drescher⁴, J Xing⁵, S Banerjee⁵ and R Wong⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Tufts Medical Center and Tufts University School of Medicine, Boston, MA, ³Centro Médico Privado de Reumatología, Tucuman, Argentina, ⁴Csolnoky Ferenc Hospital, Veszprém, Hungary, ⁵Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: New treatment options for psoriatic arthritis (PsA) are needed and interleukin-6 (IL-6), a cytokine with a central role in chronic inflammation, is a potential…
Abstract Number: 951 • 2014 ACR/ARHP Annual Meeting
Safety, Tolerability, and Functional Activity of ABT-122, a Dual TNF- and IL-17A–Targeted DVD-Ig™, Following Single-Dose Administration in Healthy Subjects
Heikki Mansikka¹, Melanie Ruzek², Margaret Hugunin², Alexander Ivanov², Alyssa Brito², Anca Clabbers², Carolyn Cuff³, Chung-Ming Hsieh², Martin Okun¹, Renee Heuser¹, David Carter¹, Barbara Hendrickson¹, Dipak Pisal¹, Sandra Goss¹, Jia Liu¹, Charles Locke¹, Nasser Khan¹ and Robert Padley¹, ¹AbbVie, Inc, North Chicago, IL, ²AbbVie, Inc, Worcester, MA, ³Immunology, AbbVie, Inc, Worcester, MA
Background/Purpose: Several lines of evidence indicate that greater clinical efficacy and protection of joints may be possible in patients with RA by neutralizing TNF and…
Abstract Number: 950 • 2014 ACR/ARHP Annual Meeting
Multiple Mechanisms of Tolerance Characterize the Immune Response to Autologous Modified Dendritic Cells Exposed to Citrullinated Peptides in Patients with Rheumatoid Arthritis
Soi-Cheng Law¹, Hendrik Nel², Ahmed Mehdi², Kim-Anh Le Cao² and Ranjeny Thomas³, ¹Diamantina Institute, Univ of Queensland, Brisbane, Australia, ²Diamantina Institute, University of Queensland, Brisbane, Australia, ³Diamantina Institute, Univ of Queensland, Brisbane, QLD, Australia
Background/Purpose We carried out a phase I clinical trial of tolerising autologous peripheral blood DCs exposed to 4 citrullinated self-peptides (“Rheumavax”) in 29 HLA-DR shared…
Abstract Number: 949 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of CF101 in Rheumatoid Arthritis Patients: A Phase II Study
Rumen M. Stoilov¹, Rodina N. Licheva², Mariyana K. Mihaylova³, Tatiana Reitblat⁴, Emil A. Dimitrov¹, Krasimira M. Shimbova¹, Girish Bhatia⁵, Amit Pispati⁶, Alexandra Gurman- Balbir⁷, B R Bagaria⁵, Boytcho A. Oparanov², Sari Fishman⁸, Zivit Harpaz⁸, Motti Farbstein⁸, Shira Cohen⁸, Michael H. Silverman⁸ and Pnina Fishman⁸, ¹Multiprofile Hospital for Active Treatment “Sv. Ivan Rilski” - EAD, Clinic of Rheumatology, Sofia, Bulgaria, ²Diagnostic Consulting Center, Rheumatology office, Sofia, Bulgaria, ³3Diagnostic Consulting Center, Rheumatology office, Sofia, Bulgaria, ⁴Barzilai Medical Center,, Ashkelon, Israel, ⁵Malpani Multispeciality Hospital, mumbai, India, ⁶Bhatia Hospital Medical Research Society, mumbai, India, ⁷Rambam Medical Center, Haifa, Israel, ⁸CanFite Biopharma Ltd, Petah Tikva, Israel
Background/Purpose: CF101, is a highly selective A3 adenosine receptor (A3AR) agonist, demonstrated safety and anti-inflammatory effect in Phase 2 clinical studies of rheumatoid arthritis (RA)…
Abstract Number: 948 • 2014 ACR/ARHP Annual Meeting
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate
Alan J. Kivitz¹, Anna Zubrzycka-Sienkiewicz², Sergio R. Gutierrez-Ureña³, Jeffrey Poiley⁴, Rita Kristy⁵, Kathyjo Shay⁵ and Jay P. Garg⁵, ¹Altoona Center for Clinical Research, Duncansville, PA, ²ARS Rheumatica sp. Zo.o, Reumatika, Warszawa, Poland, ³Hospital Civil de Guadalajara FAA, CUCS UdG, Guadalajara, Mexico, ⁴Arthritis Associates, Orlando, FL, ⁵Astellas Pharma Global Development, Northbrook, IL
Background/Purpose ASP015K is a novel oral Janus kinase (JAK) inhibitor in development for the treatment of rheumatoid arthritis (RA). ASP015K inhibits JAK 1/3 with relative…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].